骨质疏松与系统性硬化症患者抗拓扑异构酶I抗体阳性及糖皮质激素使用相关
本研究基于里尔大学医院485例符合ACR/EULAR 2013诊断标准的系统性硬化症患者的前瞻性队列,回顾性收集骨健康数据。骨质疏松患病率为23%,脆性骨折发生率为18%。多因素分析显示高龄(OR 1.06)、抗拓扑异构酶I抗体阳性(OR 2.22)和糖皮质激素治疗(OR 4.48)与骨质疏松独立相关。
要点
- 系统性硬化症患者骨质疏松患病率为23%,脆性骨折发生率为18%。
- 多因素分析中,高龄、抗拓扑异构酶I抗体阳性和糖皮质激素治疗与骨质疏松独立相关。
- 抗拓扑异构酶I抗体阳性者骨质疏松风险约为阴性者的2.22倍。
核心结论
- 系统性硬化症患者骨质疏松风险由年龄、疾病相关因素(弥漫性皮肤亚型、间质性肺病、抗拓扑异构酶I抗体阳性)以及糖皮质激素治疗独立于其他因素所决定。
研究设计与样本
- 横断面研究,基于一个大型前瞻性系统性硬化症患者队列,回顾性收集骨健康数据。
- 共纳入485例符合ACR/EULAR 2013诊断标准、在里尔大学医院随访的系统性硬化症患者。
主要发现
- 骨质疏松患病率为23%,脆性骨折发生于18%的患者。
- 单因素分析中,骨质疏松与较高年龄、弥漫性皮肤亚型、间质性肺病、抗拓扑异构酶I抗体阳性、糖皮质激素治疗及DMARDs治疗相关。
- 多因素分析显示,较高年龄(OR 1.06 [95%CI 1.04-1.08])、抗拓扑异构酶I抗体阳性(OR 2.22 [1.18-4.16])和糖皮质激素治疗(OR 4.48 [2.42-8.26])与骨质疏松显著且独立相关。
关键数值与推荐
- 骨质疏松定义为股骨颈或腰椎T值低于-2.5、既往发生重大骨质疏松性骨折或处方抗骨质疏松治疗。
- 系统性硬化症诊断依据ACR/EULAR 2013诊断标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc. METHODS: This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy. RESULTS: A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04-1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18-4.16]) and treatment with GC (OR 4.48 [2.42-8.26]) were significantly and independently associated with OP. CONCLUSION: Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.
引用
- Midol C, Wiebe E, Siegert E, et al. Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 38452356. doi:10.1093/rheumatology/keae142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。